Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | DBH | P09172 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899617 | 0.86 | CA2 (0.41) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL10345419 | 0.86 | CA2 (0.41) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL77974 | 0.83 | CA2 (0.61) | ALDH1A1KDM4ECA2 | |
| SCHEMBL4380153 | 0.83 | ALDH1A1 (0.49) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL10667947 | 0.83 | MAPT (0.48) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL28122001 | 0.82 | MAPT (0.50) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL21328361 | 0.80 | CA2 (0.52) | ALDH1A1KDM4ECA2 | |
| SCHEMBL21328358 | 0.80 | CA2 (0.52) | ALDH1A1KDM4ECA2 | |
| SCHEMBL29689736 | 0.80 | CRHBP (0.46) | MAPTSMN1; SMN2HTTALDH1A1KDM4E | |
| SCHEMBL1438454 | 0.80 | CRHBP (0.46) | MAPTSMN1; SMN2HTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250122152-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-17 | — | — | US | disclosed |
| WO-2025068943-A1 | KAT6 INHIBITORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024240726-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-11-28 | — | — | WO | disclosed |
| CN-117069724-A | Fused ring compounds, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-113493438-B | Tetrahydroisoquinoline compounds | 南京再明医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-6933294-B2 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1490371-A1 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058930-A1 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-25 | — | — | US | disclosed |
| WO-2003084959-A1 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
| US-4460604-A | ANALGESICS, NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1984-07-17 | — | — | US | disclosed |
| US-4180584-A | ANALGESIC; NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-3984559-A | Compositions comprising tetramic acid analogs of pulvinic acid and methods of combating arthritis | SMITHKLINE CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
| US-3947580-A | Anti-arthritic compositions comprising N-heterocyclic pulvinic acid amides and methods of producing anti-arthritic activity | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
| US-3931207-A | ANTIARTHRITIC | SMITHKLINE CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058930-A1 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | ABCG2, PFAS, CYP2F1 | MAPT 2887/4885SMN1; SMN2 4802/4885L3MBTL1 3639/4885 |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | MAPT 68/4885SMN1; SMN2 1922/4885L3MBTL1 200/4885 |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | MAPT 4827/4885SMN1; SMN2 3016/4885L3MBTL1 1663/4885 |
| US-20250122152-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT7 | MAPT 34/4885SMN1; SMN2 1499/4885L3MBTL1 1315/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | MAPT 1222/4885SMN1; SMN2 2143/4885L3MBTL1 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.